<DOC>
	<DOCNO>NCT02977962</DOCNO>
	<brief_summary>Autism spectrum disorder ( ASD ) affect approximately 1.1 % late adolescent young adult , make one common neurodevelopmental disorder . Comorbid anxiety disorder affect many higher-functioning adolescent young adult ASD , cause substantial distress impairment cause ASD diagnosis alone . While cognitive-behavioral therapy ( CBT ) first-line treatment anxiety disorder among typically develop late adolescent , work investigative team support utility child ASD comorbid anxiety , evidence-based treatment approach exist late adolescent ASD comorbid anxiety . Accordingly , investigator propose develop CBT protocol clinical anxiety personalize unique clinical characteristic late adolescent ( age 16-21 year ) ASD namely , Treatment Anxiety Late Adolescents Autism ( TALAA ) .</brief_summary>
	<brief_title>Treatment Anxiety Late Adolescents With Autism</brief_title>
	<detailed_description>Autism spectrum disorder ( ASD ) affect approximately 1.1 % late adolescent young adult , make one common neurodevelopmental disorder . Comorbid anxiety disorder affect many higher-functioning adolescent young adult ASD , cause substantial distress impairment cause ASD diagnosis alone . While cognitive-behavioral therapy ( CBT ) first-line treatment anxiety disorder among typically develop late adolescent , work investigative team support utility child ASD comorbid anxiety , evidence-based treatment approach exist late adolescent ASD comorbid anxiety . Accordingly , investigator propose develop CBT protocol clinical anxiety personalize unique clinical characteristic late adolescent ( age 16-21 year ) ASD namely , Treatment Anxiety Late Adolescents Autism ( TALAA ) . Initial TALAA development effort focus adapt relevant treatment element efficacious CBT program early adolescent ASD comorbid anxiety characteristic clinical need age group . Developmentally appropriate , novel treatment component add , include focus foster successful transition adulthood ( e.g. , work readiness ) . In response NIH Roadmap Initiative , attention pay protocol adaptability vary clinical presentation . Measures treatment integrity competence develop . Thereafter , protocol measure development refine experience treat 8 young adult ( age 16-21 year ) ASD comorbid anxiety disorder ( ) well clinician , patient , expert feedback . The feasibility implement TALAA examine context pilot study incorporate feature plan future efficacy trial compare TALAA treatment usual , limited sample size ( N=44 ) .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<criteria>Outpatient male female ASD age 1621 year consent/assent . The individual meet criteria ASD . The individual meet criteria clinically significant anxiety symptom . Meets criteria diagnosis one follow anxiety disorder : separation anxiety disorder ( SAD ) , specific phobia , panic disorder ( PD ) , generalize anxiety disorder ( GAD ) , social phobia ( SP ) , obsessive compulsive disorder ( OCD ) minimum score 14 Hamilton Anxiety Scale . Person Full Scale IQ approximation &gt; 70 assessed Wechsler Abbreviated Scale IntelligenceII two four subtest form . Receiving concurrent psychotherapy focus anxiety . Initiation antidepressant medication within 12 week study enrollment antipsychotic medication 6 week study enrollment child change dose establish medication within 8 week study enrollment ( 4 week antipsychotic ) psychotherapy ( unless dose lower side effect ) . ( ) Current clinically significant suicidality ( b ) individual engage suicidal behavior within 6 month exclude referred appropriate clinical intervention . Lifetime bipolar disorder , schizophrenia schizoaffective disorder , substance abuse past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>